Hypothesis

ANRIL functions as a context‑dependent scaffold that toggles the CDKN2A/B locus between a repressed and an active state by recruiting either PRC2 or TET‑mediated demethylation complexes. In hematopoietic progenitors under low stress, ANLI‑PRC2 maintains H3K27me3 and keeps p16INK4a silent; sustained inflammatory or metabolic stress triggers ANRIL conformational change, releasing PRC2 and attracting TET2/TET3, leading to localized DNA demethylation, loss of H3K27me3, and a rapid, irreversible surge in p16INK4a expression that drives senescence in T‑lymphocytes and impairs insulin signaling in adipose‑derived mesenchymal stem cells.

Mechanistic Rationale

1. ANRIL’s dual binding capacity – ANRIL RNA contains distinct domains: a PRC2‑binding motif (validated in endothelial cells) and a CpG‑rich region that can recruit TET enzymes when methylated (see ANRIL promoter methylation regulating p14ARF activity 3).
2. Stress‑induced conformational switch – Oxidative stress or high glucose alters ANRIL secondary structure, reducing its affinity for EZH2 (PRC2 core) and increasing exposure of the TET‑interacting motif, analogous to stress‑responsive lncRNAs that remodel chromatin.
3. Bistable outcome – The locus exhibits hysteresis: once demethylated, p16INK4a transcription remains high even after stress removal because loss of H3K27me3 prevents PRC2 rebinding, explaining the sustained senescence commitment observed after ≥5 days of high p14ARF 6.
4. Lineage‑specific effects – In T‑cells, ANRIL‑driven p16INK4a suppresses IL‑7R signaling, reducing naive T‑cell output (lineage‑specific aging phenotype 2). In adipose progenitors, the same p16INK4a surge impairs adiponectin secretion and promotes insulin resistance, linking the locus to type 2 diabetes GWAS hits 3.

Testable Predictions

• Prediction 1: CRISPRi of the ANRIL PRC2‑binding domain will increase p16INK4a expression in resting human CD4⁺ T‑cells without altering total ANRIL levels.
• Prediction 2: Overexpression of a mutant ANRIL lacking the TET‑interacting motif will block stress‑induced p16INK4a upregulation and preserve naive T‑cell proliferation under chronic IFN‑γ exposure.
• Prediction 3: Pharmacologic inhibition of TET2 (e.g., with Bobcat339) will prevent demethylation of CpG sites within the CDKN2A promoter and attenuate p16INK4a‑mediated senescence in adipose‑derived stem cells exposed to high palmitate.
• Prediction 4: Single‑cell multi‑omics of peripheral blood from young versus aged donors will reveal a bimodal distribution of ANRIL isoform usage correlating with p16INK4a high/low states, and the high state will be enriched in donors with type 2 diabetes.

Experimental Approach

1. Cell models: Primary human naïve CD4⁺ T‑cells and adipose‑derived mesenchymal stem cells isolated from donors aged 20‑30 y and 60‑70 y.
2. Perturbations:
   • CRISPRi using dCas9‑KRAB targeting ANRIL PRC2‑binding site.
   • Lentiviral expression of wild‑type or TET‑binding‑deficient ANRIL.
   • TET2 inhibition with Bobcat339 (5 µM) or vehicle.
3. Readouts:
   • qRT‑PCR and western blot for p16INK4a, p14ARF, ANRIL isoforms.
   • DNA methylation profiling (bisulfite seq) of CDKN2A promoter CpGs.
   • ChIP‑seq for H3K27me3, EZH2, TET2 at the locus.
   • Functional assays: CFSE dilution for T‑cell proliferation, ELISA for adiponectin, SA‑β‑gal staining.
4. Analysis: Compare methylation, histone marks, and expression between conditions; use logistic regression to test whether ANRIL isoform ratio predicts p16INK4a high state independent of age.

If the data show that altering ANRIL’s protein‑binding capacity switches the locus between repressed and active states without changing ANRIL abundance, the hypothesis will be supported. Conversely, if p16INK4a remains unaffected by ANRIL domain‑specific manipulations, the model will be falsified, indicating that other regulators dominate the epigenetic control of CDKN2A/B in aging and disease.